93
Participants
Start Date
February 22, 2022
Primary Completion Date
March 19, 2025
Study Completion Date
March 19, 2025
BDB-001 injection
Intravenously administered
Cyclophosphamide
Intravenously administered
Glucocorticoids
Orally administered
Peking Union Medical College Hospital, Beijing
Tongji Hospital,Tongji Medical college of Hust, Wuhan
Peking University First Hospital, Beijing
Peking University International Hospital, Beijing
The First Hospital of China Medical University, Shenyang
Shengjing Hospital of China Medical University, Shengyang
Zhongshan hospital,Fudan University, Shanghai
The Second hospital Of Anhui Medical University, Hefei
Tianjin Medical University General Hospital, Tianjin
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou
The First Affiliated Hospital of Nanchang University, Nanchang
Xiangya Hospital Central South University (Nephrology Department), Changsha
Xiangya Hospital Central South University(Rheumatism Immunity Branch), Changsha
The Third Xiangya Hospital of Central South University, Changsha
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
The First Affiliated Hospital of Henan University of science and Technology, Luoyang
Guangxi Academy of Medical Sciences,The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning
Xijing Hospital, Xi’an
The First Affiliated Hospital of Xi'an Jiao Tong University, Xi’an
General Hospital of Ningxia Medical University, Yinchuan
The Second hospital of Hebei Medical University, Shijiazhuang
The Third hospital of Hebei Medical University, Shijiazhuang
Staidson (Beijing) Biopharmaceuticals Co., Ltd
INDUSTRY